Transpyloric Feeding in Severe Bronchopulmonary Dysplasia

Bronchopulmonary Dysplasia Clinical Trial

Official title:

Pilot N-of-1 Multiple Crossover Randomized Trial of Gastric and Transpyloric Feeds in Infants With Severe Bronchopulmonary Dysplasia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02142621
• Other study ID #: 14-010924
• Status: Completed
• Phase: N/A
• First received: May 15, 2014
• Last updated: February 2, 2018
• Start date: December 18, 2014
• Est. completion date: July 15, 2016

Study information

• Verified date: February 2018
• Source: Children's Hospital of Philadelphia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Bronchopulmonary dysplasia (BPD) is the most common complication of extreme preterm birth. It impacts 10,000-15,000 infants in the US annually, including approximately 50% of infants with birth weight < 1000g. BPD is associated with multiple long-term adverse outcomes including chronic cardiopulmonary and neurodevelopmental impairments. Infants with severe BPD, defined as a need for ≥ 30% inspired oxygen and/or mechanical respiratory support at 36 weeks postmenstrual age (PMA), suffer the greatest burden of these chronic sequelae. Recurrent episodes of hypoxemia and prolonged exposure to supplemental oxygen are linked to the development of these impairments. Gastroesophageal reflux (GER) contributes to these mechanisms by exacerbating pulmonary inflammation and inducing bronchospasm. Unfortunately, clinically available methods to diagnose GER in infants are unreliable. Moreover, acid suppressive agents are both ineffective and carry high risk of serious life-threatening morbidity. Simple transpyloric feeding has promise, but has not been evaluated in BPD.

This study will pilot N-of-1 trials to assess whether transpyloric feeds reduce airway complications of GER and and whether this methodology can aid in identifying individual infants with severe BPD who are likely to benefit from prolonged use of transpyloric feeds.

Aim 1. To determine for each enrolled infant with severe BPD whether transpyloric compared to gastric feeds reduce the number of daily intermittent hypoxemic events (primary outcome) and improve a validated BPD severity score (secondary outcome).

The investigators hypothesize that 80% percent of enrolled infants will have significantly fewer daily intermittent hypoxemic events with transpyloric compared to gastric feeds and will have this feeding method formally recommended.

Aim 2. To pool results from multiple N-of-1 trials to determine whether transpyloric compared to gastric feeds reduce airway complications of GER in infants with severe BPD.

The investigators hypothesize that transpyloric compared to gastric feeds will be associated overall with a 15% reduction in number of daily intermittent hypoxemic events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 15, 2016
• Est. primary completion date: July 15, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 24 Weeks

Eligibility

Inclusion Criteria:

• Gestational age = 32 weeks

• Severe BPD (FiO2 = 30% and/or mechanical ventilation or non-invasive positive pressure respiratory support at the time of enrollment)

• Post menstrual age of 36-45 6/7 weeks at enrollment

• Parent and/or guardian permission (informed consent)

Exclusion Criteria:

• Prior intolerance to transpyloric feeds

• History of surgical anti-reflux procedure

• Congenital heart disease (not including patent ductus arterioles and hemodynamically insignificant ventricular septal defect or atrial septal defect)

• Structural abnormalities of the upper airway, lungs, or chest wall

• Other congenital malformations or syndromes that adversely affect life expectancy or cardio-pulmonary development

• Parent, guardian, or subject who, in the opinion of the investigators, are unlikely to participate for the duration of the study

Related Conditions & MeSH terms

• Bronchopulmonary Dysplasia

Intervention

Other:
• transpyloric feeding

• gastric feeding

Locations

Country	Name	City	State
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in transient intermittent hypoxemic events every 4 days	transient hypoxemic events is defined for the purposes of this study as an oxygen saturation < 80% for = 10 seconds and < 3 minutes recorded by continuous pulse oximetry.	4 days